

PTO/SB/21 (09-04)

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/613,654
Filing Date	July 3, 2003
First Named Inventor	Keren et al.
Art Unit	3763
Examiner Name	Han, Mark K.
Attorney Docket Number	022352-000310US

**ENCLOSURES (Check all that apply)**

- |   |   |  |
|---|---|--|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Reply to Missing Parts/ Incomplete Application<br><input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____<br><input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):<br>Return Postcard<br>PTO Forms SB/08A and SB/08B<br>Copies of 16 cited references |
|---|---|--|

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Townsend and Townsend and Crew LLP
Signature	
Printed name	James M. Heslin
Date	APRIL 14, 2005

Reg. No. 29,541

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name

Tiffany Wu


Date

4/15/05

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 022352-000310US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



On 4/15/05

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]  
Tiffany Wu

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Keren et al.

Application No.: 10/613,654

Filed: July 3, 2003

For: APPARATUS AND METHODS  
FOR TREATING CONGESTIVE HEAR  
DISEASE

Examiner: Mark K. Han

Art Unit: 3763

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the Non-U.S. Patent references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no


Application No.: 10/613,654  
Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



James M. Heslin  
Reg. No. 29,541

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
JMH:rlj  
60413295 v1





<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/613,654		
		Filing Date	July 3, 2003		
		First Named Inventor	Keren et al.		
		Art Unit	3763		
		Examiner Name	Mark K. Han		
Sheet	2	of	2	Attorney Docket Number	022352-000310US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	10	AGOSTONI et al. Sustained Benefit from Ultrafiltration in Moderate Congestive heart failure Cardiology 2001:96 183-189	
	11	GRUBERG et al. The prognostic implications of further renal deterioration within 48 h of interventionary etc. J AM Coll Cardiol 2000, 20(5):540-548	
	12	HALPENNY et al. The effects of fentanyl on renal blood flow and tubular function during aortic cross-clamping in anesthetized dogs, EUR J Anesthesiol, 2000 Aug: 17(8); 491-8 Abstract	
	13	KINI et al. A protocol for Prevention of Radiographic contrast Nephropathy etc. Catheterization and Cardiovascular Interventions 2002, 55:169-173	
	14	KINI et al. Managing the High-Risk Patient: Experience with Fenoldopam etc. Rev. Cardiovas Med 2001:2(suppl 1) S19-S25	
	15	MADYOON, Use of Fenoldopam to Prevent Radiocontrast Nephropathy etc. Catheterization and Cardiovascular Interventions 2001, 53:341-345	
	16	MATHUR et al., The effects of fenoldopam, a selective dopamine receptor agonist, on renal hemodynamics etc. Abstract only. Crit Care Med Sep 1999: 27(9) 1832-1837	
	17	MULLER et al. Prevention of Contrast Media Associated Nephropathy, Arch Intern Med, Feb 2002, Vol. 162 pp. 329-336	
	18	NOHRIA et al. Medical Management of Advanced Heart Failure, JAMA, Feb. 6 2002, Vol. 162, pp. 628-640	
	19	TUMLIN et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion, AM heart J 2002; 894-903	
	20	UMRANI et al., Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats, Clin Exp Hypertens, 2002 Apr 24 (3): 207-19 Abstract only	
	21	ZACHERL et al. Periarterial Papaverine Applications Improves Intraoperative Kidney Function etc. Journal of Surgical Research 103:268-271 (2002)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.